Dechra Pharmaceuticals PLC — AGM Information 2023

Nov 14, 2023

National Storage Mechanism | Additional information

RNS Number : 4075T

Dechra Pharmaceuticals PLC

14 November 2023

Tuesday, 14 November 2023

LEI: 213800J4UVB5OWG8VX82

Dechra® Pharmaceuticals PLC

(Dechra or the Company) 

Availability of 2023 Notice of the Annual General Meeting

The Notice of the 2023 Annual General Meeting is now available to view at www.dechra.com.

The following documents will be mailed today to registered shareholders of the Company who have elected to receive postal copies:

·      Notice of the 2023 Annual General Meeting; and

·      Proxy Form for the 2023 Annual General Meeting.

In accordance with Listing Rule 9.6.1 a copy of each of these documents will be submitted to the National Storage Mechanism and will be available for viewing shortly after posting.

The Annual General Meeting is scheduled to be held on 13 December 2023 at 11.00am.

For further information, please contact:

Melanie Hall, Company Secretary

Dechra Pharmaceuticals PLC     

Telephone number: +44 (0) 1606 814730

About Dechra

Dechra is a global specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, marketing and sales of high quality products exclusively for veterinarians worldwide.  For more information please visit: www.dechra.com.

Trademarks

Trademarks appear throughout this document in italics. Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NOAUSRAROOUAAAA